Loading…
Loading…
BIO does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for BIO and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for BIO and 80,000+ other tickers.
See exactly how BIO's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for BIO and 80,000+ other tickers.
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical…
BIO-key (BKYI) secured another Middle East government contract (new customer) for its passwordless, biometric, identity & access management (IAM) solutions
On October 16, 2026, Bio-Rad Laboratories Inc (BIO) shares fell by 3.0%, bringing the current price to $353.70. The stock has experienced a 52-week range of $23
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the third quarter of 2026 on Wednesday, November 4, 2026, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) that day.To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside the.
HOLMDEL, N.J., Oct. 13, 2026 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (NASDAQ: BKYI), a global provider of workforce and customer Identity and Access Management (IAM) software featuring passwordless, phoneless and tokenless Identity-Bound Biometric™ (IBB) authentication, today announced the appointment of Stephen Morrow as President of PortalGuard®, the Company's flagship IAM platform.
BIO-key (BKYI) Adds New Middle East Government Security Agency, Expands Regional Footprint, Supports National Digital Transformation & Cybersecurity goals.